Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 249 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive discount agreements for Naltrexone (ATC N07BB04) under §130a Abs. 8 SGB V
  • Contract duration: July 1, 2025 to June 30, 2027
Afficher le résumé complet

This is an open-house model (non-procurement) for non-exclusive discount agreements on Naltrexone (ATC N07BB04) with AOK Bayern. Any eligible pharmaceutical company can join by submitting a signed declaration of reliability and signed contract documents. The contract runs from July 1, 2025 to June 30, 2027. No estimated value is provided. The notice is published under procurement forms but is explicitly stated not to be a procurement procedure.

Risques

No estimated value or framework maximum is provided. The commercial attractiveness is unknown.

Open-house agreements automatically terminate if a formal procurement-based discount contract for Naltrexone is conclud...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Eligibility: only pharmaceutical companies may participate

Administrative

  • Submission of signed contract, annex listing covered medicines, and signed declaration of reliability
  • Documents can be submitted in paper (two originals) or electronically with qualified electronic signature

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria applicable since this is an open-house model with no selection process.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Naltrexon, ATC N07BB04

Non-exclusive discount agreements for the active substance Naltrexone (ATC N07BB04). Eligible pharmaceutical companies can join at any time until May 5, 2027. Contracts are identical and not negotiable. Early termination possible with one-month notice. The open-house agreements automatically cease if a nationwide or regional discount contract is concluded via a formal procurement procedure.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria applicable since this is an open-house model with no selection process.

Date limite

Deadline May 05, 2027

Détails de la procédure

Date de publication
15 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
317360-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30